|Year : 2015 | Volume
| Issue : 3 | Page : 283-289
Clinical study on evaluation of anti-cataract effect of Triphaladi Ghana Vati and Elaneer Kuzhambu Anjana in Timira (immature cataract)
Hitesh Bhati, R Manjusha
Department of Shalakya Tantra, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
|Date of Web Publication||20-May-2016|
Ph.D. Scholar, Dept. of Shalakya Tantra, IPGT and RA, Gujarat Ayurved University, Jamnagar - 361 008, Gujarat
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Introduction: Senile cataract is the leading cause of blindness according to the World Health Report, 1998. Till date no accepted medical treatment is available for cataract. In Ayurveda visual disturbances are described in the context of Timira, Kacha and Linganasha. Timira is an early stage characterized by blurring of vision and Linganasha is end stage where complete loss of vision occurs. Ancient scholars have advocated different Anjana application and oral medications in the Timira and Kacha stage. Aim: To study the efficacy of test drugs Triphaladi Ghana Vati and Elaneer Kuzhambu Anjana in immature cataract. Materials and Methods: In this trial patients having Senile Immature Cataract were randomized with equal probability to one of the two treatment Groups A and B (n = 20 each). In Group A Triphaladi Ghana Vati 500 mg internally for 3 months and in Group B Triphaladi Ghana Vati 500 mg internally and Elaneer Kuzhambu Anjana for local application were given. Assessment was done on the basis of blurring of vision, visualization of nonexisting things, difficulty in bright light and dim light or night vision, distant visual acuity, pinhole vision, best corrected visual acuity and cataract grading on slit lamp. Results: Both groups showed statistically significant changes in blurring of vision, difficulty in glare, daytime and bright light, distant visual activity, pinhole vision, and best-corrected visual acuity. Group B also showed significant changes in difficulty in night time, visualization of nonexisting things and in nuclear cataract. Conclusion: The study establishes that test drugs can reduce and control the progress of immature cataract, and combined therapy was found more effective. Chakshushya Rasayana, early diagnosis and proper management on Doshic lines can prevent arrest or delay senile cataract.
Keywords: Cataract, Elaneer Kuzhambu Anjana, Timira, Triphaladi Ghana Vati
|How to cite this article:|
Bhati H, Manjusha R. Clinical study on evaluation of anti-cataract effect of Triphaladi Ghana Vati and Elaneer Kuzhambu Anjana in Timira (immature cataract). AYU 2015;36:283-9
|How to cite this URL:|
Bhati H, Manjusha R. Clinical study on evaluation of anti-cataract effect of Triphaladi Ghana Vati and Elaneer Kuzhambu Anjana in Timira (immature cataract). AYU [serial online] 2015 [cited 2021 Jan 21];36:283-9. Available from: https://www.ayujournal.org/text.asp?2015/36/3/283/182762
| Introduction|| |
In the West, the incidence of cataract in people over 50 years is 15%, while in developing countries it is about 40%. In the developing world, the prevalence is believed to be greater and the onset at earlier ages, making the social and medical costs of blindness from cataract highly disproportional in areas of the world that can ill afford them. Thus, senile cataract is a common and obvious ocular condition associated with dramatic effects upon vision. The World Health Report published in 1998 estimated that there were 19.34 million people who are bilaterally blind from age-related cataract. This represented 43% of all blindness. Minassian and Mehra estimated that for India alone 3.8 million people become blind from cataract each year.
The similarity between Timira and Cataract starts from the word meaning itself. Timira is derived from word Tim which means Kledane that is imbibing of moisture, increase of watery substance in the eye.Timira/cataract denotes a shade of darkness which makes the view of the patients affected by this disease as if looking through water, moisture, waterfall, glazed paper, waxed paper etc.
Till date no accepted medical treatment is available for cataract, surgery is the only available treatment for cataract. Though the prevalence of cataract blindness would decrease due to increase in cataract surgery rate, the absolute number of cataract-blind would increase from 7.75 million in 2001 to 8.25 million in 2020 due to the substantial increase in the population above 50 years in India over this period. Data available in India show that all cataract surgeries are not sight-restoring. Surgical treatment of cataract imposes great economic burden on the society, and the backlog is perhaps too big to be handled by surgery alone at the same time surgical approach have its own complications. If such a factor is identified which simply delays the onset of cataract by a period of 10 years, the number of cataract surgeries would drastically decrease by 45% or more.
Therefore, the entire world is looking at the other systems of medicine to tackle the situation and looking upon preventive ophthalmology for improving and maintaining vision. In such a scenario, a study on Immature Cataract management gains much importance. Among many anti-cataract medicines Elaneer Kuzhambu Anjana is extensively used clinically since centuries in Kerala by local physicians, however, clinical and experimental data on the efficacy are not available on this formulation. Hence, this formulation was selected for the present study. As senile cataract can be taken as Swabhava Balapravritta Vyadhi which occurs as an aging change in the body. According to Ayurveda, a Rasayana drug which contains rejuvenating properties is the best drugs to avoid senile changes, so Triphaladi Ghana Vati was selected for this trial. This drug contains 11 Ayurvedic drugs; maximum among them were having Rasayana (rejuvenating) properties.
Therefore, this study was planned with the aim to assess the efficacy of Triphaladi Ghana Vati and Elaneer Kuzhambu Anjana as anti-cataract agents.
| Materials and Methods|| |
Total forty patients, from the outpatient department of Shalakya Tantra Department, Institute of Postgraduate Teaching and Research in Ayurveda Hospital, Jamnagar, Gujarat, were registered in this Randomised Parallel Group Clinical Trial. A prior written informed consent was taken from each and every patient. Clinical study was started after getting clearance from Institutional Ethics Committee (No. PGT/7/-A/Ethics/2013–2014/1767) and study was also registered under Clinical Trial Registry of India (CTRI/2014/01/004357).
Patients of both sexes who met the diagnostic standards of Timira/immature cataract aged 30–60 years were included in this study. Participants were included on the basis symptoms like blurring of vision, visualization of nonexisting things, difficulty in bright light and dim light or night vision and signs like distant visual acuity, pinhole vision, best corrected visual acuity and cataract grading on slit lamp biomicroscopy according to Lenticular Opacity Classification System II.
Patients who are suffering from congenital cataract, mature and hyper mature cataract, glaucoma, diabetic retinopathy, macular degeneration, retinitis pigmentosa, whose random blood sugar level and blood pressure are not within normal limits, who are under steroid treatment and or any kind of immunosuppressive therapy or under any cataract-inducing medication are excluded.
Grouping and posology
All the registered patients were randomly assigned to two groups Group A and Group B (n = 20 each). Lottery method was adopted for randomization.
- Group A: Triphaladi Ghana Vati (500 mg) orally administered twice daily for 3 months
- Group B: Elaneer Kuzhambu Anjana used as Anjana, 60 mg in both eyes for topical use and Triphaladi Ghana Vati (500 mg) orally administered twice daily for 3 months.
Follow-up period was fixed as 1 month for both the groups.
The ingredients of Triphaladi Ghana Vati [Table 1] were procured from the Pharmacy, Gujarat Ayurved University, Jamnagar and Ghana-Vati was prepared. Elaneer Kuzhambu Anjana was procured from Arya Vaidya Shala, Kottakkal, Kerala (Batch no. 164292; Mfg. Jan 2014).
Criteria for assessment
- Subjective parameters visual disturbances were assessed by Snellen's chart and Jaeger's chart reading. Blurring of vision, polyopia, nyctalopia, hamarlopia, glaring of light, colored halos, visualization of nonexisting things  were assessed with the help of grading pattern
- Objective parameters were obtained by retinoscopy, slit lamp bio microscopic examination in tangentional sectioning of lens and retro-illumination technique for grading of cataract, according to Lenticular Opacity Classification System II [Figure 1] and direct and indirect ophthalmoscopic examinations were used to obtain values of objective parameters.
|Figure 1: The Lens Opacity Classification System II photographic grading standards. N: Nuclear photographs, C: Cortical photographs, P: Posterior subcapsular photographs|
Click here to view
0 – Absent
1 – Mild
2 – Moderate
3 – Severe disturbing day to day life
Visualization of nonexisting things like dots, lines, threads, etc:
0 – Absent
1 – Occasional perception
2 – Perception without disturbing routine work
3 – Severe disturbing day to day work.
Difficulty in day vision or vision in light, glare etc:
0 – No difficulty in light/day time
1 – Slight difficulty in light/day time
2 – Moderate difficulty in light/day time
3 – Severe difficulty in light/day time.
Difficult in night vision or dim light:
0 – No difficulty in night time
1 – Slight difficulty in night time
2 – Moderate difficulty in night time
3 – Severe difficulty in night time.
Unaided distant visual acuity, pinhole vision best corrected distant visual acuity (Snellen's distant vision chart)
Nuclear cataract Lenticular Opacity Classification System II [Figure 1].
Wilcoxon matched-pair signed-rank test and paired t-test were used to assess results for individual groups. Unpaired t-test and Fisher's exact test were used to calculate the comparison of results between the groups using GraphPad Instat 3.1 software (GraphPad Software Inc., California, USA).
| Observations and Results|| |
Total 36 patients completed the treatment course. Three dropouts were there in Group A and one in Group B. In Group A, three patients discontinued the treatment, two patients thought that eye diseases have to be treated with eye drops. When this group did not receive any eye drops, they dropped out and one patient was transferred to other state. In Group B, one patient dropped out the treatment as he had to undergo cataract surgery.
There was statistically significant improvement in blurring of vision and in difficulty in light, day vision, glare was found in both the groups. In addition to that Group B showed statistically significant change in visualization of nonexisting things like dots, lines, threads, etc., and difficulty in night vision or dim vision was observed [Table 2].
|Table 2: Effect of treatment on symptoms of cataract (Wilcoxon matched--pairs signed--ranks test)|
Click here to view
Statistically significant improvement in unaided distant visual acuity, pinhole vision, and in best-corrected vision was found in both the groups. Groups B also showed statistically significant reduction in nuclear cataract [Table 3].
Comparison between Group A and B
Statistically insignificant change assessed on comparison of difference between Group A and B with Fisher's exact test on symptoms such as blurred vision, visualization of nonexisting things and difficulty in light, day vision, glare, etc., Statistically significant change assessed on comparison between Group A and B with Fisher's exact test for difficulty in night vision or dim light [Table 4].
|Table 4: Comparison of difference of symptoms between Group A and B (Fisher's exact test)|
Click here to view
Statistically insignificant change was assessed on comparison between Group A and Group B with unpaired t-test on signs such as unaided distant visual acuity, pinhole vision and best-corrected vision. Statistically significant change was observed on comparison between Group A and B with unpaired t-test for nuclear cataract [Table 5].
|Table 5: Comparison of difference of signs between Group A and B (unpaired t-test)|
Click here to view
Out of 36 patients in Group A 52.94% patients showed mild improvement, 23.53% remained unchanged, moderate improvements was found in 17.65% and 5.88% showed marked improvement and no patient was cured 0%. In Group B 47.36% patients showed moderate improvement, 26.32% showed marked and mild improvement, respectively, and no patient was cured or remained unchanged [Figure 2].
| Discussion|| |
Findings of both the groups suggest that selected drugs are effective, but better results were observed in Group B where both the drugs were administered to the patients. This can be because administration of oral drug alone is not sufficient to reverse the biochemical changes happening in the whole body and to attain sufficient quantity of drug to ocular tissues. Hence, a combination of oral and local administration is a must. Anjana type of ocular drug administration keeps the drug in contact with the eye surface longer. This Kriya Kalpa was an everyday routine to Indians which prevented refractive errors and cataract. Anjana is an excellent Kalpana which gives excellent systemic results, is evident from experimental and clinical study. In this way, Elaneer Kuzhambu Anjana can arrest, delay or reverse progression of cataract.
In the present study, test drug contained the ingredients suspended in tender coconut water, which is akin to plasma concentrate thus facilitating drug absorption by ocular tissue which also enters the systemic circulation. Also, the nutritive elements in coconut water media can nourish the lens, arresting degenerative changes and promoting lens nutrition, thus reversing nuclear cataract.
This drug is having all the 6 Rasas viz. Madhura (sweet), Amla (sour), Lavana (salty), Katu (pungent), Tikta (bitter) and Kashaya (astringent); Laghu (light), Ruksha (dry), Sheeta (cold), Snigdha (unctous) and Teekshna Gunas (properties); Ushna and Sheeta Veerya Dravya; Lekhana (scrapping), Chhedaniya, Shodhana (purifying), Rasayana, Chakshushya and Tridosha Shamaka properties. Katu Rasa is having Ushna, Pachana (digestive), Kaphahara properties. Kledopashoshana (dries up moisture), Shlesmopashoshana properties are possessed by Tikta Rasa. Kashaya Rasa shows its Shoshana (absorbing), more particularly Kledashoshana and Shleshma Prashamana properties. Laghu Guna has Kaphahara properties, Lekhana property is being possessed by Tikta and Kashaya Rasa and Laghu Guna. Tikta Rasa shows its Chhedaniya property, Katu Rasa is Teekshna and possessing Marga Vivarana (expand/dilate channels) action. Because of the above said inherent properties of drug, after getting absorbed, it may scrap away the vitiated Kapha, Ama and Meda already lodged in the Patalas, Rupavaha Sira as well as in Drishti. Their Shuddha Srotasa (opened channels) allows free movement of Vata, Pitta and Pitta performs its normal function of visual perception which was previously experiencing hindrance due to vitiated Kapha. The specific activity like Kaphahara and Pittavardhaka make an overall attempt to enhance the qualities of Tarpaka Kapha and Alochaka Pitta by alleviating the disturbances related to them.
Senile cataract or Timira is a Swabhava Balapravritta Vyadhi which occurs by natural ageing process. Taking Rasayana is helpful to increase the immunity of person to keep him away from diseases which influence the fundamental aspect of body viz. Dhatus, Agni and Srotamsi and Ojas etc., Characteristic properties of polyherbal formulation Triphaladi Ghana Vati which can help in preventing, delaying and reversal of senile cataract are as follows- Triphala that is Amalaki (Emblica officinalis Linn.), Haritaki (Terminalia chebula Retz.), and Vibheetaki (Terminalia bellirica Roxb.) is having adaptogenic, antioxidant, anti-cataract, immunomodulatory, anti-diabetic, anti-hypercholesterolemic, free radical scavenger and rejuvenation properties.Tulasi (Ocimum sanctum Linn.) is having adaptogenic, antioxidant, anti-cataract, immunomodulatory, anti-diabetic, anti-hypercholesterolemic, free radical scavenger  and advanced glycation end products-inhibitor properties.Guduchi (Tinospora cordifolia Miers.) is a adaptogenic, anti-oxidant, free radical scavenger, anti-cataract, immunomodulatory, anti-diabetic, anti-hypercholesterolemic and rejuvenating drug.Haridra (Curcuma longa Linn.) is having anti-oxidant, free radical scavenger, anti-diabetic, anti-age  anti hypercholesterolemic, adaptogenic  characteristics. Daruharidra (Berberis aristata DC.) is having anti-diabetic, anti-hyperlipidemia, anti-oxidant, anti-inflammatory specially in ocular infections, eye infections, adaptogenic, immunomodulatory, anti-cataract  effect. Shunthi (Zingiber officinale Rosc.) is having advanced glycation end products-inhibitor, immunomodulatory, anti-diabetic, anti-hyperlipidemia, anti-oxidant, anti-ageing, immunomodulatory, anti-cataract, free radical scavenger  properties. Yashtimadhu (Glycyrrhiza glabra Linn.) is having antioxidant, immunomodulatory activity, anti-diabetic, Rasayana,  anti-hypercholesterolemic, enhancer of the bio-availability of drugs  like actions. Punarnava (Boerhavia diffusa Linn.) is having immunomodulatory, antioxidant, antihypercholesterolemic, potential nutrients source, adaptogenic, immunopotentiating,Rasayana like actions. Gokshura (Tribulus terrestris Linn.) is having immunomodulatory, anti-diabetic, hypolipidemic, adaptogenic, Rasayana,  antioxidant  and anti-cataract  properties. Maximum numbers of ingredients of Triphaladi Ghana Vati are having Rasayana or rejuvenating, adaptogenic, immunomodulatory, anti-diabetic and anti-cataract effect. These properties are beneficial in senile cataract.
In Ayurvedic classical texts administration of potent psycho-physical rejuvenator formulations come under Rasayana Chikitsa which frees one off the diseases, improves quality of life and delays senile degenerative changes and have Chakshushya properties that is beneficial to eye. Cataract is also an ageing disorder and possible move to delay/arrest these senile changes is to start Rasayana Chikitsa as early as possible. Chakshushya Rasayana is the best choice to delay cataract changes. Hence, Triphaladi Ghana Vati can arrest, delay, or reverse progression of cataract.
Multicentric studies with larger sample size on same drugs should be carried out to bring authenticity of results. Photo documented studies are a must so that we can demonstrate the improvement in signs. Protocol of treatment for different types of cataract with choice of drugs based on Doshas must be tried. Effect of test drugs on different morphological cataracts needs to be done.
As, till date no medical treatment is available for cataract if the test drugs prove to have anti-cataract effect, then this can reduce a lot of financial burden on patients and can be a milestone in improving healthcare system. For better recording of cataract grading a good quality photographic attachment on slit lamp biomicroscope will add great value to the objectivity and reproducibility of the result as in this study researcher found this as a limitation of the study.
| Conclusion|| |
Internal use of Triphaladi Ghana Vati along with Anjana with Elaneer Kuzhambu Anjana that is combined therapy in Group B showed better results. This can be concluded that both systemic and topical administration is required for better management of Timira (senile cataract). Chakshushya Rasayana, Chakshushya Ahara Vihara, early diagnosis and proper management on Doshic lines can prevent arrest or delay senile cataract. The clinical study establishes both the test drugs can reduce and control the progress of Timira/cataract.
Financial support and sponsorship
IPGT and RA, Gujarat Ayurved University, Jamnagar.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ohrloff C. Epidemiology of senile cataract. In: Hockwin O, Sasaki K, Leske MC, editors. Risk Factors for Cataract Development. Basel: Karger; 1989. p. 1-5.
Seddon J, Fong D, West SK, Valmadrid CT. Epidemiology of risk factors for age-related cataract. Surv Ophthalmol 1995;39:323-34.
World Health Organization. The World Health Report: Life in the 21st
Century – A Vision for All. Geneva: World Health Organization; 1998. p. 47.
Minassian DC, Mehra V. 3.8 million blinded by cataract each year: Projections from the first epidemiological study of incidence of cataract blindness in India. Br J Ophthalmol 1990;74:341-3.
Radhakant DB. Yanjana varna. In: Vaardaprasad V, Haricharan V, editor. Shabdakalpadruma Dwiteeya Kand. 2nd
ed. Delhi: Nag Publishers; 2003. p. 618.
Murthy G, Gupta SK, John N, Vashist P. Current status of cataract blindness and Vision 2020: The right to sight initiative in India. Indian J Ophthalmol 2008;56:489-94.
Limburg H, Foster A, Vaidyanathan K, Murthy GV. Monitoring visual outcome of cataract surgery in India. Bull World Health Organ 1999;77:455-60.
Rajagopala M, Singh K, Mankodi HJ, Bavalatti N. Role of Manahshiladi Anjana and Jeevantyadi Ghrita
-cataract. Ayu 2009;30(4):409.
Anekkaleelil SG, Aravattazhikathu KV. Urdhwanga Roga Chikitsa. In: Sahasrayogam, Sujanpriya Commentary. 26th
ed. Mullakkal, Alappuzha: Vidyarambham Publisher; 2006. p. 390.
Chylack LT Jr., Leske MC, McCarthy D, Khu P, Kashiwagi T, Sperduto R. Lens opacities classification system II (LOCS II) Arch Ophthalmol 1989;107:991-7.
Khurana AK. Diseases of the lens. In: Khurana B, editor. Comprehensive Ophthalmology. 5th
ed. New Delhi: New Age International [P] Limited Publishers; 2012. p. 189-90.
Varma RK. Evaluation of Anti-Cataract Effect of Triphaladi yoga
and Elaneer kuzhambu
on Experimental and Clinical Immature Cataract w.s.r. to Timira. PhD [Dissertation]. Jamnagar: Gujarat Ayurved University; 2013.
Gowda DV, Muguli G, Rangesh PR, Deshpande RD. Phytochemical and pharmacological actions of Triphala: Ayurvedic formulation – A review. Int J Pharm Sci Rev Res 2012;15:61-5.
Chouhan B, Kumawat RC, Kotecha M, Nathani S. Triphala: A comprehensive Ayurvedic review. Int J Res Ayurveda Pharm 2013;4:612-7.
Cohen MM. Tulsi – Ocimum sanctum
: A herb for all reasons. J Ayurveda Integr Med 2014;5:251-9.
Saraswat M, Reddy PY, Muthenna P, Reddy GB. Prevention of non-enzymic glycation of proteins by dietary agents: Prospects for alleviating diabetic complications. Br J Nutr 2009;101:1714-21.
Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six Rasayana herbs used in Ayurvedic medicine. Phytother Res 1999;13:275-91.
Premanath R, Lakshmi Devi N. Studies on anti-oxidant activity of Tinospora cordifolia
[Miers.] leaves using in vitro
models. J Am Sci 2010;6:736-43.
Saha S, Ghosh S. Tinospora cordifolia
: One plant, many roles. Anc Sci Life 2012;31:151-9.
Singh SS, Pandey SC, Srivastava S, Gupta VS, Patro B, Ghosh AC. Chemistry and medicinal properties of Tinospora cordifolia
[Guduchi]. Indian J Pharmacol 2003;35:83-91.
Ramadan G, Al-Kahtani MA, El-Sayed WM. Anti-inflammatory and anti-oxidant properties of Curcuma longa
[Turmeric] versus Zingiber officinale
[Ginger] rhizomes in rat adjuvant-induced arthritis. Inflammation 2011;34:291-301.
Araújo CC, Leon LL. Biological activities of Curcuma longa
L. Mem Inst Oswaldo Cruz 2001;96:723-8.
Pandya MG, Mehta N, Khagram R. Therapeutic importance of Haridra [Curcuma longa
LINN.] In the management of Madhumeha WSR to Diabetes Mellitus-TYPE 2 [NIDDM]. Word J Pharm Pharm Sci 2015;4:355-69.
Shahaji FA. A review on Alzheimer's disease and its concepts in Ayurveda. Int J Ayurveda Pharma Res 2015;3:52-6.
Manisha T, Kumar MS, Reetu S. Effect of Rasayana in communicable diseases: A review. Int J Ayurvedic Med 2015;6:1-7.
Tamilselvi S, Balasubramani SP, Venkatasubramanian P, Vasanthi NS. A review on the pharmacognosy and pharmacology of the herbals traded as 'Daruharidra'. Int J Pharm Bio Sci 2014;5:556-70.
Saravanakumar T, Venkatasubramanian P, Vasanthi NS, Manonmani E. Antimicrobial potential of Daruharidra [Berberis aristata
DC] against the pathogens causing eye infection. Int J Green Pharm 2014;8:153-7.
Singh J, Kakkar P. Antihyperglycemic and antioxidant effect of Berberis aristata
root extract and its role in regulating carbohydrate metabolism in diabetic rats. J Ethnopharmacol 2009;123:22-6.
Mazumder PM, Das S, Das MK. Phyto-pharmacology of Berberis aristata
DC: A review. J Drug Deliv Ther 2011;1:46-51.
Meena AK, Pal B, Singh B, Yadav AK, Singh U, Kaur R, et al
. A review on cataract and its herbal treatments. J Drug Invent Today 2010;2:178-81.
Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale
Roscoe): A review of recent research. Food Chem Toxicol 2008;46:409-20.
Manikandaselvi S, Vadivel V, Brindha P. Nutraceuticals – An overview. Int J Pharm Bio Sci 2016;7:284-96.
Bhatt N, Waly MI, Essa MM, Ali A. Ginger: A Functional Herb. Available from: https://www.researchgate.net/profile/Mostafa_Waly2/publication/257416254_Ginger_a_functional_herb/links/0deec538e156f37e9a000000.pdf. [Last accessed on 2016 Feb 17].
Kaur R, Kaur H, Dhindsa AS. Glycyrrhiza glabra
: A phytopharmacological review. Int J Pharm Sci Res 2013;4:2470-7.
Saxena S. Glycyrrhiza glabra
: Medicine over the millennium. Nat Prod Rad 2005;4:358-67.
Visavadiya NP, Narasimhacharya AV. Hypocholesterolaemic and antioxidant effects of Glycyrrhiza glabra
(Linn) in rats. Mol Nutr Food Res 2006;50:1080-6.
Khanuja SP, Kumar S, Arya JS, Shasany AK, Singh M, Awasthi S, et al
. Plant Extracts from Glycyrrhiza glabra
; Glycyrrhizin; Bio-Enhancers and Bioavailability Facilitators for Anti-Infectives, Anti-Cancer Agents; Non-Toxic. United States Patent US 6,979,471; 27 December, 2005.
Satheesh MA, Pari L. Antioxidant effect of Boerhavia diffusa
L. in tissues of alloxan induced diabetic rats. Indian J Exp Biol 2004;42:989-92.
Ujowundu CO, Igwe CU, Enemor VH, Nwaogu LA, Okafor OE. Nutritive and anti-nutritive properties of Boerhavia diffusa
and Commelina nudiflora
leaves. Pak J Nutr 2008;7:90-2.
Sumanth M, Mustafa SS. Antistress, adoptogenic and immunopotentiating activity roots of Boerhaavia diffusa
in mice. Int J Pharmacol 2007;3:416-20.
Rajpoot K, Mishra RN. Boerhaavia Diffusa
roots [Punarnava mool] – Review as Rasayan [Rejuvenator/antiaging]. Int J Pharm Biomed Res 2011;2:1451-60.
Chhatre S, Nesari T, Somani G, Kanchan D, Sathaye S. Phytopharmacological overview of Tribulus terrestris
. Pharmacogn Rev 2014;8:45-51.
Shivakumar H, Javed T, Prakash T, Rao RN, Swamy BJ, Goud AV. Adaptogenic activity of ethanolic extract of Tribulus terrestris
L. J Nat Remedies 2006;6:87-95.
Zheleva-Dimitrova DI, Obreshkova DA, Nedialkov P. Antioxidant activity of Tribulus terrestris
– A natural product in infertility therapy. Int J Pharm Pharm Sci 2012;4:508-11.
Gacche RN, Dhole NA. Profile of aldose reductase inhibition, anti-cataract and free radical scavenging activity of selected medicinal plants: An attempt to standardize the botanicals for amelioration of diabetes complications. Food Chem Toxicol 2011;49:1806-13.
Shastri LP. Rasayana adhikara. In: Shastri BS. Yog Ratnakara. 7th
ed. Varanasi: Chaukhmabha Sanskrit Sansthan; 2002. p. 498.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]
|This article has been cited by|
||Medicinal Plants and Natural Products Used in Cataract Management
| ||Devesh Tewari,Ovidiu Samoila,Diana Gocan,Andrei Mocan,Cadmiel Moldovan,Hari Prasad Devkota,Atanas G. Atanasov,Gokhan Zengin,Javier Echeverrķa,Dan Vodnar,Bianca Szabo,Gianina Crisan |
| ||Frontiers in Pharmacology. 2019; 10 |
|[Pubmed] | [DOI]|